Invention Grant
- Patent Title: Xenogenic normal tissue-derived vaccines for breaking the immune tolerance to tumor-associated, antigens
-
Application No.: US15514100Application Date: 2015-04-15
-
Publication No.: US10695408B2Publication Date: 2020-06-30
- Inventor: Victor I. Seledtsov , Galina V. Seledtsova , Adas Darinskas
- Applicant: UAB “INNOVITA RESEARCH”
- Applicant Address: LT Vilnius
- Assignee: UAB “Innovita Research”
- Current Assignee: UAB “Innovita Research”
- Current Assignee Address: LT Vilnius
- Agency: Young & Thompson
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5fd6efc9
- International Application: PCT/IB2015/052738 WO 20150415
- International Announcement: WO2016/046651 WO 20160331
- Main IPC: A61K39/00
- IPC: A61K39/00

Abstract:
Disclosed is an antitumor vaccine including testicular and fetal tissue-derived components. Cell preparations are prepared from normal tissues harvested directly from animals. Such vaccines may be used in the treatment and prevention of different cancers. For example, a vaccine consisting of glutaraldehyde-treated cells prepared from sheep testis and fetal lung has been found to be effective in inducing antitumor cell-mediated responses, as well as in prolonging the survival of mice with lung cancer.
Public/Granted literature
- US20170296642A1 XENOGENIC NORMAL TISSUE-DERIVED VACCINES FOR BREAKING THE IMMUNE TOLERANCE TO TUMOR-ASSOCIATED, ANTIGENS Public/Granted day:2017-10-19
Information query